Drugs / SP16
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT05135624 | Dec 2021 → Jun 2023 | COVID-19, pneumonia | Serpin Pharma, LLC | Terminated | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT04225533 | Feb 2020 → Jan 2021 | myocardial infarction | Serpin Pharma, LLC | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT03651089 Comparator | Jul 2018 → Jan 2019 | — | Serpin Pharma, LLC | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SP16 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04225533 ↗ |
| Known as | Serpin Peptide 16 | “Serpin Peptide 16 (SP16), a Serine Protease Inhibitor (Serpin)-like, small peptide agonist” NCT03651089 ↗1“SERPIN peptide 16 (SP16) is a synthetic, selective LRP1 agonist.” PMID 35881895 ↗ Nov 2022 |
| Action | Activate | “small peptide agonist of the Low Density Lipoprotein Receptor-like Protein 1 (LRPP1)” NCT03651089 ↗ |
| Modality | Peptide | “small peptide agonist” NCT03651089 ↗ |
| Route | Subcutaneous | “subcutaneous administration” NCT03651089 ↗ |
| Target | LRP1 | “SP16 is a synthetic, selective LRP1 agonist.” PMID 35881895 ↗ Nov 2022 |